Morgan Stanley Reiterates Overweight Rating on Eli Lilly and Company (LLY)

Market Context

Eli Lilly and Company operates in the Healthcare sector. The stock currently trades at $1215.83 with a market capitalization of $906.5B. The stock has gained 33.5% over the past 52 weeks.

Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Eli Lilly and Company.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Eli Lilly and Company

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 08, 2026	Morgan Stanley	Overweight	N/A
Jul 08, 2026	Truist Securities	Buy	N/A
Jul 08, 2026	RBC Capital	Outperform	N/A
Jul 07, 2026	JP Morgan	Overweight	N/A
Jul 06, 2026	Cantor Fitzgerald	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View LLY Stock Page